🇺🇸 FDA

Intelligence Platform

Patents

Browse 49 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11969475

Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dyst

Dyne Therapeutics, Inc. · Granted Tue Apr 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11931421

Muscle targeting complexes and formulations for treating myotonic dystrophy

Dyne Therapeutics, Inc. · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11911484

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Dyne Therapeutics, Inc. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844843

Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dyst

Dyne Therapeutics, Inc. · Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11839660

Anti-transferrin receptor antibody and uses thereof

Dyne Therapeutics, Inc. · Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11833217

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Dyne Therapeutics, Inc. · Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11795234

Methods of producing muscle-targeting complexes comprising an anti-transferrin receptor an

Dyne Therapeutics, Inc. · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11795233

Muscle-targeting complex comprising an anti-transferrin receptor antibody linked to an oli

Dyne Therapeutics, Inc. · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11787869

Methods of using muscle targeting complexes to deliver an oligonucleotide to a subject hav

Dyne Therapeutics, Inc. · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11771776

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Dyne Therapeutics, Inc. · Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11759525

Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dyst

Dyne Therapeutics, Inc. · Granted Tue Sep 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11679161

Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dyst

Dyne Therapeutics, Inc. · Granted Tue Jun 20 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11672872

Anti-transferrin receptor antibody and uses thereof

Dyne Therapeutics, Inc. · Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11648318

Anti-transferrin receptor (TFR) antibody and uses thereof

Dyne Therapeutics, Inc. · Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11638761

Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dyst

Dyne Therapeutics, Inc. · Granted Tue May 02 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11633498

Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Dyne Therapeutics, Inc. · Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11633496

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Dyne Therapeutics, Inc. · Granted Tue Apr 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11518816

Methods of delivering an oligonucleotide to a subject having facioscapulohumeral muscular

Dyne Therapeutics, Inc. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11497815

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Dyne Therapeutics, Inc. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11390682

Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes t

Dyne Therapeutics, Inc. · Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11369689

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Dyne Therapeutics, Inc. · Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11286305

Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleot

Dyne Therapeutics, Inc. · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11248056

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Dyne Therapeutics, Inc. · Granted Tue Feb 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11168141

Muscle targeting complexes and uses thereof for treating dystrophinopathies

Dyne Therapeutics, Inc. · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted